Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Pharma doses first patient in belinostat plus Tarceva trial
Belinostat (PXD 101) is a Class I and II HDAC inhibitor that is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic
Belinostat (PXD 101) is a Class I and II HDAC inhibitor that is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic
SXC Health Solutions has agreed to pay $100m in cash, subject to a customary working capital adjustment, with an additional $5.5m subject to the achievement of certain performance
Under the terms of the funding agreement, which is in support of Compugen’s Pipeline Program, Baize Investments has obtained a financial interest in five designated Compugen-discovered molecules and
Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. CEL-SCI
In a filing to the Bombay Stock Exchange, Surya Pharmaceuticals said the transaction was financed through a mix of internal accruals and debt from EXIM Bank. With this
RPS offers clients a broad spectrum of outsourcing solutions ranging from globally embedded functional and cross-functional solutions to enhanced global full-service solutions. RPS CEO and chairman Daniel Perlman
Cumberland has informed the US Food and Drug Administration (FDA) of its plan to voluntarily recall these lots of Acetadote as a precautionary measure. According to the company,
MannKind claims that Afrezza is a novel, ultra rapid acting mealtime insulin therapy being developed by MannKind Corporation for the treatment of adult patients with type 1 and
As per the approval, Sinovac is required to conduct each phase of the human clinical trials in accordance with SFDA requirements, to conduct studies to assess safety and
Nuvigil is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy. In its letter to